Trial Profile
A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Bicalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms TERRAIN
- Sponsors Astellas Pharma
- 10 Feb 2018 Results of post hoc analysis evaluating the hepatic effects of enzalutamide versus comparators in controlled castration-resistant prostate cancer trials (NCT0121299; NCT00974311; NCT01664923; NCT01288911) presented at the 2018 Genitourinary Cancers Symposium
- 15 Dec 2017 This study has been completed in Germany according to European Clinical Trials Database record.
- 04 Dec 2017 Status changed from active, no longer recruiting to completed.